This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

HEXO Valuation

Q: What is the Fair Price of HEXO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

HEXO (CA$0.91) is trading below our estimate of [[fair value]] (CA$7.65)

Is HEXO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HEXO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: HEXO (CA$0.91) is trading below our estimate of fair value (CA$7.65)

Significantly Below Fair Value: HEXO is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HEXO?

Key metric: As HEXO is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for HEXO. This is calculated by dividing HEXO's market cap by their current revenue.
What is HEXO's PS Ratio?
PS Ratio	0.3x
Sales	CA$124.10m
Market Cap	CA$40.04m

HEXO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.6x
Enterprise Value/EBITDA	-1.6x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does HEXO's PS Ratio compare to its peers?

The above table shows the PS ratio for HEXO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1x
GSD Devonian Health Group	2.3x	n/a	CA$22.2m
VEXT Vext Science	1x	35.9%	CA$47.0m
MDP Medexus Pharmaceuticals	0.4x	6.5%	CA$60.4m
TIUM.U Cansortium	0.2x	n/a	US$25.7m
HEXO HEXO	0.3x	-0.7%	CA$40.0m

Price-To-Sales vs Peers: HEXO is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (12.8x).

Price to Sales Ratio vs Industry

How does HEXO's PS Ratio compare vs other companies in the CA Pharmaceuticals Industry?

25 Companies	Price / Sales	Estimated Growth	Market Cap
AYR.A Ayr Wellness	0.2x	2.6%	US$79.90m
TIUM.U Cansortium	0.2x	n/a	US$25.68m
ACRG.A.U Acreage Holdings	0.09x	n/a	US$20.65m
MRV Nuvo Pharmaceuticals	0.2x	n/a	US$11.21m

25 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: HEXO is good value based on its Price-To-Sales Ratio (0.3x) compared to the Canadian Pharmaceuticals industry average (0.9x)

Price to Sales Ratio vs Fair Ratio

What is HEXO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HEXO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.3x
Fair PS Ratio	0.1x

Price-To-Sales vs Fair Ratio: HEXO is expensive based on its Price-To-Sales Ratio (0.3x) compared to the estimated Fair Price-To-Sales Ratio (0.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst HEXO forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	n/a	CA$1.29 0%	25.9%	CA$1.65	CA$0.92	n/a	4
Nov ’25	n/a	CA$1.29 0%	25.9%	CA$1.65	CA$0.92	n/a	4
Oct ’25	n/a	CA$1.29 0%	25.9%	CA$1.65	CA$0.92	n/a	4
Sep ’25	n/a	CA$1.29 0%	25.9%	CA$1.65	CA$0.92	n/a	4
Aug ’25	n/a	CA$1.29 0%	25.9%	CA$1.65	CA$0.92	n/a	4
Jul ’25	n/a	CA$1.29 0%	25.9%	CA$1.65	CA$0.92	n/a	4
Jun ’25	n/a	CA$1.29 0%	25.9%	CA$1.65	CA$0.92	n/a	4
May ’25	n/a	CA$1.29 0%	25.9%	CA$1.65	CA$0.92	n/a	4
Apr ’25	n/a	CA$1.29 0%	25.9%	CA$1.65	CA$0.92	n/a	4
Mar ’25	n/a	CA$1.29 0%	25.9%	CA$1.65	CA$0.92	n/a	4
Feb ’25	n/a	CA$1.29 0%	25.9%	CA$1.65	CA$0.92	n/a	4
Jan ’25	n/a	CA$1.29 0%	25.9%	CA$1.65	CA$0.92	n/a	4
Dec ’24	n/a	CA$1.29 0%	25.9%	CA$1.65	CA$0.92	n/a	4
Nov ’24	n/a	CA$1.29 0%	25.9%	CA$1.65	CA$0.92	n/a	4
Oct ’24	n/a	CA$1.29 0%	25.9%	CA$1.65	CA$0.92	n/a	4
Sep ’24	n/a	CA$1.29 0%	25.9%	CA$1.65	CA$0.92	n/a	4
Aug ’24	n/a	CA$1.29 0%	25.9%	CA$1.65	CA$0.92	n/a	4
Jul ’24	CA$0.88	CA$1.29 +46.9%	25.9%	CA$1.65	CA$0.92	n/a	4
Jun ’24	CA$1.30	CA$1.64 +26.2%	5.2%	CA$1.75	CA$1.50	n/a	5
May ’24	CA$1.68	CA$1.64 -2.4%	5.2%	CA$1.75	CA$1.50	n/a	5
Apr ’24	CA$1.81	CA$1.95 +7.9%	40.5%	CA$3.50	CA$0.80	n/a	7
Mar ’24	CA$2.25	CA$2.54 +12.9%	25.2%	CA$3.50	CA$1.40	n/a	8
Feb ’24	CA$2.13	CA$2.57 +20.6%	25.2%	CA$3.50	CA$1.40	n/a	8
Jan ’24	CA$1.39	CA$2.71 +95.1%	20.1%	CA$3.50	CA$1.40	n/a	8
Dec ’23	CA$3.15	CA$3.26 +3.3%	26.4%	CA$4.20	CA$1.40	n/a	8
Nov ’23	CA$3.50	CA$3.34 -4.4%	40.4%	CA$5.60	CA$1.40	n/a	9

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Medexus Pharmaceuticals

CA$60.4m

Operates as a pharmaceutical company in Canada and the United States.

MDP

CA$2.45

9.4%

69.0%

Verano Holdings

CA$722.2m

Operates as a vertically integrated multi-state cannabis operator in the United States.

VRNO

CA$2.02

-15.5%

-65.2%

Fennec Pharmaceuticals

US$145.9m

Operates as a biopharmaceutical company in the United States.

FRX

US$7.35

29.4%

-35.8%